Belper NewsPenny's planned a year of fund-raisingBelper NewsPenny has received her second treatment of Rituximab and her condition was already showing some small signs of stabilising. “I am so grateful for the kindness and generosity of everyone …
Ripley TodayPenny's planned a year of fund-raisingRipley TodayPenny has received her second treatment of Rituximab and her condition was already showing some small signs of stabilising. “I am so grateful for the kindness and generosity of everyon…
MedPage TodayNew Guidelines Focus on Early RA TreatmentMedPage TodayRituximab (Rituxan) can be used for patients who were treated for a solid tumor or nonmelanoma skin cancer within the previous 5 years. Rituximab also can be used when the patient has …
Excitement Over Ibrutinib Responses in Aggressive LymphomasMedscapeSince the addition of rituximab to chemotherapy, there have been no advances in the treatment of DLBCL, explained Dr. Staudt. "We are able to cure about half of all patients,"…
New guidelines offer guidance on how and when to switch between RA drug classesNews-Medical.netAlso important are biological agents, which include tumor necrosis factor-inhibitors etanercept and infliximab and non-TNF biologicals abatacept, tocilizumab…
Early Autoimmune Therapy Helps Autoimmune Epilepsy PatientsMedical News Today"Certainly trials as to which immunotherapy (steroids, intravenous immunoglobulin, cyclosporine, rituximab) is best would be ethical. We need an increased appreciation of…
US rheumatologists continue to increase use of biologics for RA treatmentThe Pharma LetterThese products include Bristol-Myers Squibb's Orencia SC (abatacept), and Genentech/Roche's Rituxan (rituximab) and Actemra (tocilizumab). The share incre…
For Those Wondering About Progress on Rituximab Trials for Chronic Fatigue …ProHealthWe know that: researchers collaborating with the Cedars-Sinai Chronic Fatigue Syndrome Research Center have planned to take part in Rituximab research, and Dr. Kogel…
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial …MarketWatch (press release)… sapacitabine in combination with cyclophosphamide and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL) or sma…
Rituxan and Avastin do not infringe Sanofi's CMV enhancer patentsLexology (registration)The Court of Appeals for the Federal Circuit recently upheld a summary judgement decision that neither rituximab nor trastuzumab infringes two Sanofi patents (5…